From: Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
---|---|---|---|---|---|
(n = 160) | (n = 76) | (n = 61) | (n = 52) | (n = 36) | |
MD | 19.8 ± 9.0 | 6.9 ± 5.2* | 9.1 ± 7.7* | 8.7 ± 8.7* | 8.8 ± 8.0* |
HD | 23.4 ± 7.3 | 11.0 ± 8.2* | 12.0 ± 8.5* | 12.0 ± 9.6* | 11.3 ± 8.7* |
Headache free days | 3.8 ± 5.7 | 7.8 ± 8.2** | 11.5 ± 10.1** | 11.6 ± 10.3** | 13.3 ± 10.3** |
Abortive treatment intake days | 11.6 ± 8.8 | 5.6 ± 5.9* | 7.4 ± 7.8** | 6.4 ± 6.8** | 6.2 ± 5.1** |
HIT-6 | 67.6 ± 4.9 | 56.7 ± 7.7** | 57.5 ± 9.0** | 58.0 ± 9.6** | 54.5 ± 8.2** |